Esperion Therapeutics ESPR Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total Revenues by Product | ||||||
| Collaboration revenue | $36.71M+22.0% | $124.76M+232% | $46.7M+128% | $42.11M+68.4% | $30.1M-73.4% | |
| Royalty Revenue From DSE And Sale Of Bulk Tablets And Milestones Received | $32.7M+11.2% | $33.4M+28.0% | $45M+120% | $41M-9.7% | $29.4M-74.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Esperion Therapeutics break its business down?
- Esperion Therapeutics (ESPR) reports total revenues by product across 2 parts — Collaboration revenue and Royalty Revenue From DSE And Sale Of Bulk Tablets And Milestones Received. Each is extracted from the segment footnotes and tracked over time.
- Where does Esperion Therapeutics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Esperion Therapeutics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
